BiotechTube
Vectorb2b

Vectorb2b

Lisbon, Portugal· Est.
vectorb2b.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

VectorB2B is a Portuguese full-service CRO founded in 2019, providing integrated drug development services from pre-clinical toxicology to late-phase clinical trials. It operates as a one-stop-shop, combining in-house expertise with a consortium of renowned academic and industrial shareholders to offer tailored, cost-competitive solutions. The company's value proposition centers on strong project management, maintaining client IP rights, and leveraging its Portuguese base for regulatory and cost advantages in serving the European market.

Digital Health

Technology Platform

Integrated CRO service platform spanning pre-clinical (including GLP toxicology) to clinical development (Phase I-IV), leveraging a consortium of academic and industrial partners for expertise and facilities.

Opportunities

Capitalizing on Portugal's cost-competitive and EMA-aligned regulatory environment to serve European biotechs seeking quality, integrated services at lower cost.
Growth through EU innovation networks like the EIC Service Catalogue and the expanding Portuguese life sciences ecosystem.

Risk Factors

Revenue vulnerability to downturns in biotech funding.
Intense competition from large global CROs and lower-cost regions.
Operational risks associated with the execution of complex, regulated studies critical to client success.

Competitive Landscape

Competes with large global full-service CROs (e.g., IQVIA, ICON) on service integration and with niche regional CROs on cost and flexibility. Its unique differentiator is its shareholder consortium of Portuguese academic/industrial leaders and ownership of Portugal's only in vivo GLP toxicology facility.

More companies in Small Molecule Drugs →More companies in Portugal →